Guest guest Posted September 4, 2010 Report Share Posted September 4, 2010  souds like he can't tollerate vit A in the carrots, and may have fat digestion issues confused> > > Interested in trying MB12 with my son but a pubmed search gave me this article. UC is pretty reputable I believe, so now I want to hear from you is it a "WOW" for anyone and in what areas? Can improvement be measured?> > J Altern Complement Med. 2010 May;16(5):555-60.> > Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism.> Bertoglio K, Jill S, Deprey L, Brule N, Hendren RL.> > 1 Department of Psychiatry and Behavioral Sciences, University of California , Medical Center, Sacramento, CA.> > Abstract> Abstract Objectives: The study objectives were to determine whether methyl B12 treatment improves behavioral measures in children with autism and whether improvement is associated with increased plasma concentrations of glutathione (GSH) and an increased redox ratio of reduced glutathione to oxidized glutathione (GSH/GSSG), both of which have been previously identified to be low in children with autism. Design: This was a 12-week, double-blind, placebo-controlled, cross-over clinical trial of injectable methyl B12. Following this 12-week study, subjects were given the option of entering a 6-month open-label trial of methyl B12. Settings/location: All procedures took place at the UC M.I.N.D. Institute. Subjects: Subjects were 3 to 8 years old with autism. Interventions: All subjects received 6 weeks of placebo and 6 weeks of methyl B12 at a dose of 64.5 mcg/kg every three days administered subcutaneously into the buttocks. Outcome measures: Blood> for GSH analysis and behavioral assessments were obtained at baseline, week 6, and week 12. Results: Thirty (30) subjects completed the 12-week, double-blind study and 22 subjects completed the 6-month extension study. No statistically significant mean differences in behavior tests or in glutathione status were identified between active and placebo groups. Nine (9) subjects (30%) demonstrated clinically significant improvement on the Clinical Global Impression Scale and at least two additional behavioral measures. More notably, these responders exhibited significantly increased plasma concentrations of GSH and GSH/GSSG. Conclusions: Comparison of the overall means between groups suggests that methyl B12 is ineffective in treating behavioral symptoms of autism. However, detailed data analysis suggests that methyl B12 may alleviate symptoms of autism in a subgroup of children, possibly by reducing oxidative stress. An increase in glutathione redox status> (GSH/GSSG) may provide a biomarker for treatment response to methyl B12. Additional research is needed to delineate a subgroup of potential responders and ascertain a biomarker for response to methyl B12.> > PMID: 20804367 [PubMed - in process]> All help is welcome> thanks,> Jeff> Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 4, 2010 Report Share Posted September 4, 2010 I'm not sure if it is the A because he does fine with other forms of A. It may be the sugars- galactose and arabinose. We are looking into this. Sent from my iPhone  souds like he can't tollerate vit A in the carrots, and may have fat digestion issues confused> > > Interested in trying MB12 with my son but a pubmed search gave me this article. UC is pretty reputable I believe, so now I want to hear from you is it a "WOW" for anyone and in what areas? Can improvement be measured?> > J Altern Complement Med. 2010 May;16(5):555-60.> > Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism.> Bertoglio K, Jill S, Deprey L, Brule N, Hendren RL.> > 1 Department of Psychiatry and Behavioral Sciences, University of California , Medical Center, Sacramento, CA.> > Abstract> Abstract Objectives: The study objectives were to determine whether methyl B12 treatment improves behavioral measures in children with autism and whether improvement is associated with increased plasma concentrations of glutathione (GSH) and an increased redox ratio of reduced glutathione to oxidized glutathione (GSH/GSSG), both of which have been previously identified to be low in children with autism. Design: This was a 12-week, double-blind, placebo-controlled, cross-over clinical trial of injectable methyl B12. Following this 12-week study, subjects were given the option of entering a 6-month open-label trial of methyl B12. Settings/location: All procedures took place at the UC M.I.N.D. Institute. Subjects: Subjects were 3 to 8 years old with autism. Interventions: All subjects received 6 weeks of placebo and 6 weeks of methyl B12 at a dose of 64.5 mcg/kg every three days administered subcutaneously into the buttocks. Outcome measures: Blood> for GSH analysis and behavioral assessments were obtained at baseline, week 6, and week 12. Results: Thirty (30) subjects completed the 12-week, double-blind study and 22 subjects completed the 6-month extension study. No statistically significant mean differences in behavior tests or in glutathione status were identified between active and placebo groups. Nine (9) subjects (30%) demonstrated clinically significant improvement on the Clinical Global Impression Scale and at least two additional behavioral measures. More notably, these responders exhibited significantly increased plasma concentrations of GSH and GSH/GSSG. Conclusions: Comparison of the overall means between groups suggests that methyl B12 is ineffective in treating behavioral symptoms of autism. However, detailed data analysis suggests that methyl B12 may alleviate symptoms of autism in a subgroup of children, possibly by reducing oxidative stress. An increase in glutathione redox status> (GSH/GSSG) may provide a biomarker for treatment response to methyl B12. Additional research is needed to delineate a subgroup of potential responders and ascertain a biomarker for response to methyl B12.> > PMID: 20804367 [PubMed - in process]> All help is welcome> thanks,> Jeff> Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 4, 2010 Report Share Posted September 4, 2010 I'm not sure if it is the A because he does fine with other forms of A. It may be the sugars- galactose and arabinose. We are looking into this. Sent from my iPhone  souds like he can't tollerate vit A in the carrots, and may have fat digestion issues confused> > > Interested in trying MB12 with my son but a pubmed search gave me this article. UC is pretty reputable I believe, so now I want to hear from you is it a "WOW" for anyone and in what areas? Can improvement be measured?> > J Altern Complement Med. 2010 May;16(5):555-60.> > Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism.> Bertoglio K, Jill S, Deprey L, Brule N, Hendren RL.> > 1 Department of Psychiatry and Behavioral Sciences, University of California , Medical Center, Sacramento, CA.> > Abstract> Abstract Objectives: The study objectives were to determine whether methyl B12 treatment improves behavioral measures in children with autism and whether improvement is associated with increased plasma concentrations of glutathione (GSH) and an increased redox ratio of reduced glutathione to oxidized glutathione (GSH/GSSG), both of which have been previously identified to be low in children with autism. Design: This was a 12-week, double-blind, placebo-controlled, cross-over clinical trial of injectable methyl B12. Following this 12-week study, subjects were given the option of entering a 6-month open-label trial of methyl B12. Settings/location: All procedures took place at the UC M.I.N.D. Institute. Subjects: Subjects were 3 to 8 years old with autism. Interventions: All subjects received 6 weeks of placebo and 6 weeks of methyl B12 at a dose of 64.5 mcg/kg every three days administered subcutaneously into the buttocks. Outcome measures: Blood> for GSH analysis and behavioral assessments were obtained at baseline, week 6, and week 12. Results: Thirty (30) subjects completed the 12-week, double-blind study and 22 subjects completed the 6-month extension study. No statistically significant mean differences in behavior tests or in glutathione status were identified between active and placebo groups. Nine (9) subjects (30%) demonstrated clinically significant improvement on the Clinical Global Impression Scale and at least two additional behavioral measures. More notably, these responders exhibited significantly increased plasma concentrations of GSH and GSH/GSSG. Conclusions: Comparison of the overall means between groups suggests that methyl B12 is ineffective in treating behavioral symptoms of autism. However, detailed data analysis suggests that methyl B12 may alleviate symptoms of autism in a subgroup of children, possibly by reducing oxidative stress. An increase in glutathione redox status> (GSH/GSSG) may provide a biomarker for treatment response to methyl B12. Additional research is needed to delineate a subgroup of potential responders and ascertain a biomarker for response to methyl B12.> > PMID: 20804367 [PubMed - in process]> All help is welcome> thanks,> Jeff> Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 4, 2010 Report Share Posted September 4, 2010 More info on phenols and symptoms: http://healingautismandadhd.wordpress.com/diet-2/phenolssalicylates/ Joanne > > > > > > One of the best things I did for my son. His processing was screwed up and confused. Right after we started MB-12, we saw big gains (within days) and the connections in his brain just started firing. For example, before he would guess and get colors correct about 40% of the time. 3 days after his first shot, he just new them all. In the beginning if we missed a day, or towards the 3rd day, (we gave every 3rd day), he would have problems like pausing in the middle of saying something, and acting confused sometimes. The morning after his shot, he was right on and quick. He is recovered now, but I still give MB-12 shots and the diet. I have tried coming off both of those, but he just doesn't do well without them. I know MB-12 does wonders for my son. I hate giving shots every time I do it (almost 2 years now), but the benefits outweigh the thought of sticking him with a needle. If I didn't notice a big difference, I wouldn't do it anymore. It is > > different for every kid, but for my son, it was big. (we did other biomedical stuff too, not just diet and MB-12) > > > > From: jeffkingsfancollins <jeffkingsfancollins@> > > To: mb12 valtrex > > Sent: Thu, September 2, 2010 3:56:28 PM > > Subject: confused > > > > > > Interested in trying MB12 with my son but a pubmed search gave me this article. UC is pretty reputable I believe, so now I want to hear from you is it a " WOW " for anyone and in what areas? Can improvement be measured? > > > > J Altern Complement Med. 2010 May;16(5):555-60. > > > > Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism. > > Bertoglio K, Jill S, Deprey L, Brule N, Hendren RL. > > > > 1 Department of Psychiatry and Behavioral Sciences, University of California , Medical Center, Sacramento, CA. > > > > Abstract > > Abstract Objectives: The study objectives were to determine whether methyl B12 treatment improves behavioral measures in children with autism and whether improvement is associated with increased plasma concentrations of glutathione (GSH) and an increased redox ratio of reduced glutathione to oxidized glutathione (GSH/GSSG), both of which have been previously identified to be low in children with autism. Design: This was a 12-week, double-blind, placebo-controlled, cross-over clinical trial of injectable methyl B12. Following this 12-week study, subjects were given the option of entering a 6-month open-label trial of methyl B12. Settings/location: All procedures took place at the UC M.I.N.D. Institute. Subjects: Subjects were 3 to 8 years old with autism. Interventions: All subjects received 6 weeks of placebo and 6 weeks of methyl B12 at a dose of 64.5 mcg/kg every three days administered subcutaneously into the buttocks. Outcome measures: Blood > > for GSH analysis and behavioral assessments were obtained at baseline, week 6, and week 12. Results: Thirty (30) subjects completed the 12-week, double-blind study and 22 subjects completed the 6-month extension study. No statistically significant mean differences in behavior tests or in glutathione status were identified between active and placebo groups. Nine (9) subjects (30%) demonstrated clinically significant improvement on the Clinical Global Impression Scale and at least two additional behavioral measures. More notably, these responders exhibited significantly increased plasma concentrations of GSH and GSH/GSSG. Conclusions: Comparison of the overall means between groups suggests that methyl B12 is ineffective in treating behavioral symptoms of autism. However, detailed data analysis suggests that methyl B12 may alleviate symptoms of autism in a subgroup of children, possibly by reducing oxidative stress. An increase in glutathione redox status > > (GSH/GSSG) may provide a biomarker for treatment response to methyl B12. Additional research is needed to delineate a subgroup of potential responders and ascertain a biomarker for response to methyl B12. > > > > PMID: 20804367 [PubMed - in process] > > All help is welcome > > thanks, > > Jeff > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 5, 2010 Report Share Posted September 5, 2010 Wonderful, thanks!Sent from my iPhone More info on phenols and symptoms: http://healingautismandadhd.wordpress.com/diet-2/phenolssalicylates/ Joanne > > > > > > One of the best things I did for my son. His processing was screwed up and confused. Right after we started MB-12, we saw big gains (within days) and the connections in his brain just started firing. For example, before he would guess and get colors correct about 40% of the time. 3 days after his first shot, he just new them all. In the beginning if we missed a day, or towards the 3rd day, (we gave every 3rd day), he would have problems like pausing in the middle of saying something, and acting confused sometimes. The morning after his shot, he was right on and quick. He is recovered now, but I still give MB-12 shots and the diet. I have tried coming off both of those, but he just doesn't do well without them. I know MB-12 does wonders for my son. I hate giving shots every time I do it (almost 2 years now), but the benefits outweigh the thought of sticking him with a needle. If I didn't notice a big difference, I wouldn't do it anymore. It is > > different for every kid, but for my son, it was big. (we did other biomedical stuff too, not just diet and MB-12) > > > > From: jeffkingsfancollins <jeffkingsfancollins@> > > To: mb12 valtrex > > Sent: Thu, September 2, 2010 3:56:28 PM > > Subject: confused > > > > > > Interested in trying MB12 with my son but a pubmed search gave me this article. UC is pretty reputable I believe, so now I want to hear from you is it a "WOW" for anyone and in what areas? Can improvement be measured? > > > > J Altern Complement Med. 2010 May;16(5):555-60. > > > > Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism. > > Bertoglio K, Jill S, Deprey L, Brule N, Hendren RL. > > > > 1 Department of Psychiatry and Behavioral Sciences, University of California , Medical Center, Sacramento, CA. > > > > Abstract > > Abstract Objectives: The study objectives were to determine whether methyl B12 treatment improves behavioral measures in children with autism and whether improvement is associated with increased plasma concentrations of glutathione (GSH) and an increased redox ratio of reduced glutathione to oxidized glutathione (GSH/GSSG), both of which have been previously identified to be low in children with autism. Design: This was a 12-week, double-blind, placebo-controlled, cross-over clinical trial of injectable methyl B12. Following this 12-week study, subjects were given the option of entering a 6-month open-label trial of methyl B12. Settings/location: All procedures took place at the UC M.I.N.D. Institute. Subjects: Subjects were 3 to 8 years old with autism. Interventions: All subjects received 6 weeks of placebo and 6 weeks of methyl B12 at a dose of 64.5 mcg/kg every three days administered subcutaneously into the buttocks. Outcome measures: Blood > > for GSH analysis and behavioral assessments were obtained at baseline, week 6, and week 12. Results: Thirty (30) subjects completed the 12-week, double-blind study and 22 subjects completed the 6-month extension study. No statistically significant mean differences in behavior tests or in glutathione status were identified between active and placebo groups. Nine (9) subjects (30%) demonstrated clinically significant improvement on the Clinical Global Impression Scale and at least two additional behavioral measures. More notably, these responders exhibited significantly increased plasma concentrations of GSH and GSH/GSSG. Conclusions: Comparison of the overall means between groups suggests that methyl B12 is ineffective in treating behavioral symptoms of autism. However, detailed data analysis suggests that methyl B12 may alleviate symptoms of autism in a subgroup of children, possibly by reducing oxidative stress. An increase in glutathione redox status > > (GSH/GSSG) may provide a biomarker for treatment response to methyl B12. Additional research is needed to delineate a subgroup of potential responders and ascertain a biomarker for response to methyl B12. > > > > PMID: 20804367 [PubMed - in process] > > All help is welcome > > thanks, > > Jeff > > > Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.